The shares of NantKwest Inc. (NASDAQ:NK) has been pegged with a rating of Sell by Citigroup in its latest research note that was published on May 31, 2019. Citigroup wasn’t the only research firm that published a report of NantKwest Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Sell rating from Citigroup Markets when it published its report on October 17, 2018. Citigroup was of a view that NK is Sell in its latest report on May 16, 2017. FBR & Co. thinks that NK is worth Outperform rating. This was contained in the firm’s report on March 17, 2017 in which the stock’s price target was also moved to 9.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $4.00. The price of the stock the last time has raised by 457.89% from its 52-Week high price while it is -22.06% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 63.26.
The shares of the company added by 8.16% during the trading session on Wednesday, reaching a low of $4.50 while ending the day at $5.30. During the trading session, a total of 2.62 million shares were traded which represents a -216.41% decline from the average session volume which is 827350.0 shares. NK had ended its last session trading at $4.90. NantKwest Inc. debt-to-equity ratio currently stands at 0.01, while its quick ratio hovers at 5.70 NK 52-week low price stands at $0.95 while its 52-week high price is $6.80.
The NantKwest Inc. generated 18.29 million in revenue during the last quarter. NantKwest Inc. has the potential to record -0.74 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Oppenheimer published a research note on October 24, 2019 where it informed investors and clients that Nektar Therapeutics (NASDAQ:NKTR) is now rated as Perform. Their price target on the stock stands at $18. Goldman also rated NKTR as Downgrade on October 08, 2019, with its price target of $16 suggesting that NKTR could surge by 27.81% from its current share price. Even though the stock has been trading at $27.96/share, analysts expect it to down by -15.99% to reach $32.54/share. It started the day trading at $25.565 and traded between $22.75 and $23.49 throughout the trading session.
A look at its technical shows that NKTR’s 50-day SMA is 21.07 while its 200-day SMA stands at 25.54. The stock has a high of $47.11 for the year while the low is $15.64. The stock, however, witnessed a rise in its short on 12/31/19. Compared to previous close which recorded 30.9 M shorted shares, the short percentage went lower by -4.90%, as 29.39M NK shares were shorted. The company’s average trading volume currently stands at 2.69M shares, which means that the short-interest ratio is just 11.48 days. Over the past seven days, the company moved, with its shift of 7.95%. Looking further, the stock has raised 35.82% over the past 90 days while it lost -26.55% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Invesco Advisers, Inc. bought more NKTR shares, increasing its portfolio by 47.35% during the last quarter. This move now sees The Invesco Advisers, Inc. purchasing 10,244,470 shares in the last quarter, thus it now holds 31,879,750 shares of NKTR, with a total valuation of $688,124,404. PRIMECAP Management Co. meanwhile bought more NKTR shares in the recently filed quarter, changing its stake to $412,774,747 worth of shares.
Similarly, The Vanguard Group, Inc. decreased its Nektar Therapeutics shares by 3.70% during the recently filed quarter. After selling 17,606,402 shares in the last quarter, the firm now controls -675,556 shares of Nektar Therapeutics which are valued at $380,034,187. In the same vein, Wellington Management Co. LLP decreased its Nektar Therapeutics shares by during the most recent reported quarter. The firm bought 3,520,643 shares during the quarter which decreased its stakes to 16,500,943 shares and is now valued at $356,172,855. Following these latest developments, around 1.30% of Nektar Therapeutics stocks are owned by institutional investors and hedge funds.